[Usefulness and safety of bunazosin hydrochloride in neurogenic bladder after prolonged administration]. 1992

S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
Kidney Center, Tokai University School of Medicine.

Bunazosin hydrochloride (Ea-0643), a selective alpha 1-blocker, was administered to 14 patients with neurogenic bladder over prolonged periods of time in order to determine its efficacy and safety. Subjective symptoms were classified into 4 grades, and their response assessed after 12 weeks of treatment. The proportion of patients showing improvement by at least one grade was 50.0% for retarded urination, 16.7% for prolonged urination, 25.0% for urinary stream condition, 25.0% for abdominal pressure at voiding, and 28.6% for residual urine. Objective symptoms were also assessed after 12 weeks of treatment, and a statistically significant improvement was recognized in the volume of spontaneously voided urine, the maximum and mean flow rates on uroflowmetry. It should be noted that both of those flow rates had improved significantly only 2 weeks into the treatment. The degree of improvement in subjective and objective symptoms and the degree of general improvement were all higher at week 12 than at week 2 of treatment. Current knowledge of the mechanism of action of this drug, coupled with the observations made in this study, suggests that, once it has improved the urodynamics, it exhibits a sustained effect for prolonged periods of treatment. However, further studies are warranted concerning the mechanisms of the pharmacological action of the drug from a pathological viewpoint. The proportion of patients in whom Ea-0643 was judged to be useful at 12 weeks of treatment was 41.7%, but when the assessment of 'slightly useful' was taken into consideration, the usefulness rate rose as high as 91.7%. Stomatitis was observed in only one case as a side effect of this drug.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D001750 Urinary Bladder, Neurogenic Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES. Bladder Disorder, Neurogenic,Neurogenic Bladder,Bladder Neurogenesis,Bladder, Neurogenic,Neurogenic Bladder Disorder,Neurogenic Bladder, Atonic,Neurogenic Bladder, Spastic,Neurogenic Bladder, Uninhibited,Neurogenic Dysfunction of the Urinary Bladder,Neurogenic Urinary Bladder Disorder,Neurogenic Urinary Bladder, Atonic,Neurogenic Urinary Bladder, Spastic,Neurogenic Urinary Bladder, Uninhibited,Neuropathic Bladder,Urinary Bladder Disorder, Neurogenic,Urinary Bladder Neurogenesis,Urinary Bladder Neurogenic Dysfunction,Atonic Neurogenic Bladder,Neurogenesis, Bladder,Neurogenesis, Urinary Bladder,Neurogenic Bladder Disorders,Neurogenic Urinary Bladder,Spastic Neurogenic Bladder,Uninhibited Neurogenic Bladder
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
November 1990, Hinyokika kiyo. Acta urologica Japonica,
S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
September 1987, Hinyokika kiyo. Acta urologica Japonica,
S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
October 1990, Hinyokika kiyo. Acta urologica Japonica,
S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
January 1989, Hinyokika kiyo. Acta urologica Japonica,
S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
June 1986, Hinyokika kiyo. Acta urologica Japonica,
S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
March 1984, Hinyokika kiyo. Acta urologica Japonica,
S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
April 1996, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
March 1959, Journal of the American Medical Association,
S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
January 1989, International journal of clinical pharmacology research,
S Hiraga, and T Satoh, and R Kakehi, and S Kojima, and M Yokokawa, and S Gotoh, and F Kaneoya, and T Mizuo, and A Tanizawa, and K Hosoda
April 1995, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
Copied contents to your clipboard!